The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML.
Qiao X, Ma J, Knight T, Su Y, Edwards H, Polin L, Li J, Kushner J, Dzinic SH, White K, Wang J, Lin H, Wang Y, Wang L, Wang G, Taub JW, Ge Y.
Qiao X, et al. Among authors: ma j.
Blood Cancer J. 2021 Jun 7;11(6):111. doi: 10.1038/s41408-021-00502-7.
Blood Cancer J. 2021.
PMID: 34099621
Free PMC article.